Epilepsy: randomised trials and genetic tribulations

The Lancet Neurology

Volumn 7, Issue 1, 2008, Pages 7-8

  Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PROTEIN DERIVATIVE; SCN1A PROTEIN; SCN1B PROTEIN; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ARTICLE; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; EPILEPSY; FOCAL EPILEPSY; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; HEALTH ECONOMICS; HUMAN; KAPLAN MEIER METHOD; LOW DRUG DOSE; MYOCLONUS EPILEPSY; PRIORITY JOURNAL; QUALITY OF LIFE; SEIZURE; SYNAPSE VESICLE; TEMPORAL LOBE EPILEPSY;

EID: 37049018793     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70301-0     Document Type: Note

References (5)

1. Brodie M., Perucca E., Ryvlin P., Ben-Menachem E., Meencke H.-J., and for the Levetiracetam Study Group. Comparison of levetiracetam and carbamazepine monotherapy in newly diagnosed epilepsy. Neurology 67 (2007) 402-408
2. Marson A., Al-Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1000-1015
3. Marson A., Al-Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassified epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1016-1026
4. Harkin L., McMahon J., Iona X., et al. The spectrum of SCN1A-related infantile epileptic encephalopathies. Brain 130 (2007) 843-852
5. + phenotypes associated with SCN1B mutations. Brain 130 (2007) 100-109